PPT-Switch to DRV/r

monotherapy MONOI MONET PROTEA DRV600 Design Objective Non inferiority in the proportion of patients with HIV1 RNA lt 50 c mL at W48 ITT analysis missingdiscontinuationswitch failure snapshot algorithm. We use switches in circuit-switched and packet-switched networks. In this section, we discuss the structures of the switches used in each type of network.. Structure of Circuit switches. Structure of Packet switches. Planning and . Implementation. July 2015. 1. Contents. Polio Endgame Objective 2. Rationale for switching from tOPV to bOPV. Dates and timelines around the Switch. Guidance for implementation:. Plan. Optimization. Aggelos Lazaris (USC), Daniel Tahara (Yale),. Xin Huang (CYAN), Li Erran Li (Bell Labs), Andreas Voellmy (Yale), Y. Richard Yang (Yale), Minlan Yu (USC). 1. ACM CoNEXT 2014. Motivation. PREfast. for Drivers. Donn. Terry . Software Design Engineer. Microsoft Corporation. Key Takeaways. Be a leader in advancing 64-bit computing. Adopt best practices and new tools. Let’s partner on new hardware directions. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . Study. NVP vs ATV/r . ARTEN . EFV vs ATV/r . A5202. DOR vs DRV/r. DRIVE-FORWARD. Design. Objective. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, . Bob Combs. Hyper-V Networking. Microsoft Corporation. VIR307. Agenda. What networking in the cloud means. So what’s new in the Hyper-V virtual switch. What is a Hyper-V Extensible Switch. Give me details!. Statements. switch . (expression) {. case . value1:. . statement(s);. . break. ;. case . value2:. statement(s);. break. ;. . ….. case . valueN. :. statement(s);. . break. ;. default: . vs. PI/r . monotherapy. Study PIVOT. Study MOBIDIP. LPV/r monotherapy (N = 82). Design. Randomisation. 1: 1. Open-label. Objective. Primary endpoint. : failure rate at W96 by ITT, defined as 1) a confirmed HIV . SPARE . Study. SPARE Study: switch to DRV/r + RAL . Design. Age ≥ . 20. years. HIV+. HIV-1 RNA. < 50 c/ml > 15 weeks. On LPV/r + TDF/FTC. No prior . virologic. failure. on PI/r- or INSTI-containing regimen. STRATEGY-PI . Study. STRATEGY-NNRTI . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (mITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -12%, 85% power. If non-inferiority and lower margin > 0, assessment for superiority. Capacity Penalties . Incremental Start Cost / Trip Risk. Gas Penalties. Breach of Bilateral Obligations / Liquidated Damages. Right of Private Action Exemption (SPP). Capacity Example. A switchable resource may be obligated to offer into a neighboring grid (must-offer obligation) as a consequence of a successful offer into an organized capacity market. . DRV/r 800/100 + 3TC 300 QD. N = 126. N = 123. DRV/r + ABC/3TC or TDF/FTC QD. Design. Randomisation*. 1: 1. Open-label. Objective. Non inferiority of DRV/r + 3TC at W48: % HIV RNA < 50 c/mL by intention to treat-exposed, snapshot analysis (lower margin of the 2-sided 95% CI for the difference = - 12%, 80% power). /r and . Metabolic . Parameters . METABOLIK. DRV/r . versus . ATV/r . and Metabolic Parameters . METABOLIK. : . Study Design . Source. : . Aberg. JA, et al. AIDS Res Hum Retroviruses. . 2012;28:. 1184-95..